JP2020516588A - オメガ3食物サプリメントにおけるアスピリン不使用のアスピリン誘発性レゾルビン類の作製 - Google Patents
オメガ3食物サプリメントにおけるアスピリン不使用のアスピリン誘発性レゾルビン類の作製 Download PDFInfo
- Publication number
- JP2020516588A JP2020516588A JP2019552124A JP2019552124A JP2020516588A JP 2020516588 A JP2020516588 A JP 2020516588A JP 2019552124 A JP2019552124 A JP 2019552124A JP 2019552124 A JP2019552124 A JP 2019552124A JP 2020516588 A JP2020516588 A JP 2020516588A
- Authority
- JP
- Japan
- Prior art keywords
- aspirin
- composition
- methyl salicylate
- subject
- sodium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000015872 dietary supplement Nutrition 0.000 title claims description 25
- 238000002360 preparation method Methods 0.000 title description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 claims abstract description 116
- 239000000203 mixture Substances 0.000 claims abstract description 92
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims abstract description 89
- 229960001138 acetylsalicylic acid Drugs 0.000 claims abstract description 88
- 238000000034 method Methods 0.000 claims abstract description 70
- 229960001047 methyl salicylate Drugs 0.000 claims abstract description 53
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims abstract description 43
- 229930064664 L-arginine Natural products 0.000 claims abstract description 43
- 235000014852 L-arginine Nutrition 0.000 claims abstract description 43
- 150000001875 compounds Chemical class 0.000 claims abstract description 30
- 230000002411 adverse Effects 0.000 claims abstract description 16
- 238000011065 in-situ storage Methods 0.000 claims abstract description 15
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims abstract 10
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 52
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 40
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 39
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 39
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims description 39
- 229940042585 tocopherol acetate Drugs 0.000 claims description 29
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 25
- 230000000694 effects Effects 0.000 claims description 18
- 239000013589 supplement Substances 0.000 claims description 18
- 210000002784 stomach Anatomy 0.000 claims description 17
- 239000003826 tablet Substances 0.000 claims description 16
- 239000000243 solution Substances 0.000 claims description 15
- 229930003427 Vitamin E Natural products 0.000 claims description 13
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 13
- 229940046009 vitamin E Drugs 0.000 claims description 13
- 239000011709 vitamin E Substances 0.000 claims description 13
- 235000019165 vitamin E Nutrition 0.000 claims description 13
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 claims description 12
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 claims description 12
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 claims description 12
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims description 12
- 229940088594 vitamin Drugs 0.000 claims description 12
- 229930003231 vitamin Natural products 0.000 claims description 12
- 235000013343 vitamin Nutrition 0.000 claims description 12
- 239000011782 vitamin Substances 0.000 claims description 12
- 239000000047 product Substances 0.000 claims description 11
- -1 oleyl succinate Chemical compound 0.000 claims description 10
- 239000009637 wintergreen oil Substances 0.000 claims description 10
- 239000003995 emulsifying agent Substances 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 9
- 239000006071 cream Substances 0.000 claims description 8
- 239000007897 gelcap Substances 0.000 claims description 8
- 239000006210 lotion Substances 0.000 claims description 8
- 230000009437 off-target effect Effects 0.000 claims description 8
- 241001061264 Astragalus Species 0.000 claims description 7
- 235000006533 astragalus Nutrition 0.000 claims description 7
- 235000013871 bee wax Nutrition 0.000 claims description 7
- 239000012166 beeswax Substances 0.000 claims description 7
- 229940092738 beeswax Drugs 0.000 claims description 7
- 210000002966 serum Anatomy 0.000 claims description 7
- 210000004233 talus Anatomy 0.000 claims description 7
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 6
- BTBJBAZGXNKLQC-UHFFFAOYSA-N ammonium lauryl sulfate Chemical compound [NH4+].CCCCCCCCCCCCOS([O-])(=O)=O BTBJBAZGXNKLQC-UHFFFAOYSA-N 0.000 claims description 6
- 229940063953 ammonium lauryl sulfate Drugs 0.000 claims description 6
- ZWXYEWJNBYQXLK-UHFFFAOYSA-N azanium;4-dodecoxy-4-oxo-3-sulfobutanoate Chemical compound [NH4+].CCCCCCCCCCCCOC(=O)C(S(O)(=O)=O)CC([O-])=O ZWXYEWJNBYQXLK-UHFFFAOYSA-N 0.000 claims description 6
- GVGUFUZHNYFZLC-UHFFFAOYSA-N dodecyl benzenesulfonate;sodium Chemical compound [Na].CCCCCCCCCCCCOS(=O)(=O)C1=CC=CC=C1 GVGUFUZHNYFZLC-UHFFFAOYSA-N 0.000 claims description 6
- BOUCRWJEKAGKKG-UHFFFAOYSA-N n-[3-(diethylaminomethyl)-4-hydroxyphenyl]acetamide Chemical compound CCN(CC)CC1=CC(NC(C)=O)=CC=C1O BOUCRWJEKAGKKG-UHFFFAOYSA-N 0.000 claims description 6
- 230000002829 reductive effect Effects 0.000 claims description 6
- 108700004121 sarkosyl Proteins 0.000 claims description 6
- 239000011734 sodium Substances 0.000 claims description 6
- 229910052708 sodium Inorganic materials 0.000 claims description 6
- 229940083542 sodium Drugs 0.000 claims description 6
- 229940080264 sodium dodecylbenzenesulfonate Drugs 0.000 claims description 6
- 229940057950 sodium laureth sulfate Drugs 0.000 claims description 6
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 6
- SXHLENDCVBIJFO-UHFFFAOYSA-M sodium;2-[2-(2-dodecoxyethoxy)ethoxy]ethyl sulfate Chemical compound [Na+].CCCCCCCCCCCCOCCOCCOCCOS([O-])(=O)=O SXHLENDCVBIJFO-UHFFFAOYSA-M 0.000 claims description 6
- ADWNFGORSPBALY-UHFFFAOYSA-M sodium;2-[dodecyl(methyl)amino]acetate Chemical compound [Na+].CCCCCCCCCCCCN(C)CC([O-])=O ADWNFGORSPBALY-UHFFFAOYSA-M 0.000 claims description 6
- 239000000829 suppository Substances 0.000 claims description 6
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 6
- 235000018185 Betula X alpestris Nutrition 0.000 claims description 5
- 235000018212 Betula X uliginosa Nutrition 0.000 claims description 5
- 235000011201 Ginkgo Nutrition 0.000 claims description 5
- 235000008100 Ginkgo biloba Nutrition 0.000 claims description 5
- 239000006172 buffering agent Substances 0.000 claims description 5
- 238000011049 filling Methods 0.000 claims description 5
- 238000001990 intravenous administration Methods 0.000 claims description 5
- 241000208173 Apiaceae Species 0.000 claims description 4
- 208000002193 Pain Diseases 0.000 claims description 4
- 238000007918 intramuscular administration Methods 0.000 claims description 4
- 238000007912 intraperitoneal administration Methods 0.000 claims description 4
- 238000007920 subcutaneous administration Methods 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 3
- 239000000872 buffer Substances 0.000 claims description 2
- 230000009084 cardiovascular function Effects 0.000 claims description 2
- 241000218628 Ginkgo Species 0.000 claims 3
- 238000010586 diagram Methods 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 26
- 239000003814 drug Substances 0.000 description 26
- 229940079593 drug Drugs 0.000 description 24
- 239000002552 dosage form Substances 0.000 description 22
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 17
- 229940090949 docosahexaenoic acid Drugs 0.000 description 13
- 239000004480 active ingredient Substances 0.000 description 11
- 230000003110 anti-inflammatory effect Effects 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 238000013268 sustained release Methods 0.000 description 11
- 239000012730 sustained-release form Substances 0.000 description 11
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- 239000008187 granular material Substances 0.000 description 9
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 235000002639 sodium chloride Nutrition 0.000 description 8
- 239000000463 material Substances 0.000 description 7
- 150000003839 salts Chemical group 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 235000021323 fish oil Nutrition 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- 239000008297 liquid dosage form Substances 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 102000010907 Cyclooxygenase 2 Human genes 0.000 description 5
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 238000013270 controlled release Methods 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000013376 functional food Nutrition 0.000 description 4
- 239000007903 gelatin capsule Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 150000004703 alkoxides Chemical class 0.000 description 3
- 239000007900 aqueous suspension Substances 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- AOPOCGPBAIARAV-OTBJXLELSA-N resolvin E1 Chemical compound CC[C@@H](O)\C=C\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O AOPOCGPBAIARAV-OTBJXLELSA-N 0.000 description 3
- 238000009490 roller compaction Methods 0.000 description 3
- 235000015424 sodium Nutrition 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 230000001960 triggered effect Effects 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
- 244000194101 Ginkgo biloba Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 241001092387 Spiraea Species 0.000 description 2
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000002051 biphasic effect Effects 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000007891 compressed tablet Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000006207 intravenous dosage form Substances 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- ONWPLBKWMAUFGZ-UHFFFAOYSA-N methyl 2-acetyloxybenzoate Chemical compound COC(=O)C1=CC=CC=C1OC(C)=O ONWPLBKWMAUFGZ-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 229940012843 omega-3 fatty acid Drugs 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000006201 parenteral dosage form Substances 0.000 description 2
- 239000003182 parenteral nutrition solution Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 239000004633 polyglycolic acid Substances 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- OIWTWACQMDFHJG-CCFUIAGSSA-N resolvin D1 Chemical compound CC\C=C/C[C@H](O)\C=C\C=C/C=C/C=C/[C@@H](O)[C@@H](O)C\C=C/CCC(O)=O OIWTWACQMDFHJG-CCFUIAGSSA-N 0.000 description 2
- QBTJOLCUKWLTIC-UZAFJXHNSA-N resolvin D3 Chemical compound CC\C=C/C[C@H](O)\C=C\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCC(O)=O QBTJOLCUKWLTIC-UZAFJXHNSA-N 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 239000002691 unilamellar liposome Substances 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- GVJHHUAWPYXKBD-QLVXXPONSA-N (S,R,R)-alpha-tocopherol Chemical compound [H][C@@](C)(CCCC(C)C)CCC[C@@]([H])(C)CCC[C@@]1(C)CCC2=C(O1)C(C)=C(C)C(O)=C2C GVJHHUAWPYXKBD-QLVXXPONSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000003826 Artemisia Nutrition 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 229930184725 Lipoxin Natural products 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 241000042032 Petrocephalus catostoma Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 241000222350 Pleurotus Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 235000002634 Solanum Nutrition 0.000 description 1
- 241000207763 Solanum Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 241000272195 Vultur Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229920000469 amphiphilic block copolymer Polymers 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003070 anti-hyperalgesia Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000009052 artemisia Nutrition 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- OIWTWACQMDFHJG-BJEBZIPWSA-N aspirin-triggered resolvin D1 Chemical compound CC\C=C/C[C@@H](O)\C=C\C=C/C=C/C=C/[C@@H](O)[C@@H](O)C\C=C/CCC(O)=O OIWTWACQMDFHJG-BJEBZIPWSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000002902 bimodal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000036996 cardiovascular health Effects 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 238000009223 counseling Methods 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 230000005595 deprotonation Effects 0.000 description 1
- 238000010537 deprotonation reaction Methods 0.000 description 1
- QTBSBXVTEAMEQO-DYCDLGHISA-N deuterio acetate Chemical compound [2H]OC(C)=O QTBSBXVTEAMEQO-DYCDLGHISA-N 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229940013317 fish oils Drugs 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000010952 in-situ formation Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002639 lipoxins Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- HWPKGOGLCKPRLZ-UHFFFAOYSA-M monosodium citrate Chemical compound [Na+].OC(=O)CC(O)(C([O-])=O)CC(O)=O HWPKGOGLCKPRLZ-UHFFFAOYSA-M 0.000 description 1
- 235000018342 monosodium citrate Nutrition 0.000 description 1
- 239000002524 monosodium citrate Substances 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 229920002721 polycyanoacrylate Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- CRDZYJSQHCXHEG-SFVBTVKNSA-N protectin D1 Chemical compound CC\C=C/C[C@H](O)\C=C/C=C/C=C/[C@H](O)C\C=C/C\C=C/CCC(O)=O CRDZYJSQHCXHEG-SFVBTVKNSA-N 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/10—Foods or foodstuffs containing additives; Preparation or treatment thereof containing emulsifiers
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
本発明の組成物を使用するための投与単位は混合され、イオン又は共役結合を形成し得る。本発明のサリチル酸メチル、酢酸d,l−α−トコフェロール、及びL−アルギニンは、経口、静脈内(ボーラスもしくは注入)、腹腔内、皮下、又は筋内剤形で投与され得、すべて医薬分野の当業者に周知の剤形が用いられる。特定の位置又は送達方法に応じて、治療を必要とする患者に本発明のサリチル酸メチル、酢酸d,l−α−トコフェロール、及びL−アルギニンを与えるために、錠剤、カプセル、丸剤、散剤、顆粒剤、エリキシル剤、チンキ剤、懸濁剤、シロップ剤、及び乳剤などの異なる剤形が使用され得る。サリチル酸メチル、酢酸d,l−α−トコフェロール、及びL−アルギニンは、公知の塩形態のいずれか1つとしても投与され得る。
Groeger, et al., Cyclooxygenase−2 generates anti−inflammatory mediators from omega−3 fatty acids, NATURE CHEMICAL BIOLOGY, Vol. 6, June 2010, 433−441.
Serhan, et al., Resolvins: A Family of Bioactive Products of Omega−3 Fatty Acid Transformation Circuits Initiated by Aspirin Treatment that Counter Proinflammation Signals, J. Exp. Med., Volume 196, Number 8, October 21, 2002 1025-1037.
Dalli, et al., Resolvin D3 and Aspirin−Triggered Resolvin D3 Are Potent Immunoresolvents, Chemistry & Biology 20, 188-201, February 21, 2013.
Serhan, et al., Novel Proresolving Aspirin−Triggered DHA Pathway, Chemistry & Biology 18, 976-987, August 26, 2011.
Serhan, et al., Novel Functional Sets of Lipid−derived Mediators with Antiinflammatory Actions Generated from Omega−3 Fatty Acids via Cyclooxygenase 2-Nonsteroidal Antiinflammatory Drugs and Transcellular Processing, J. Exp. Med., Volume 192, Number 8, October 16, 2000 1197-1204.
Chen, C., COX−2’s new role in inflammation, NATURE CHEMICAL BIOLOGY, Vol 6, June 2010, 401−402.
Serhan, C., Novel Pro−Resolving Lipid Mediators in Inflammation Are Leads for Resolution Physiology, Nature. 2014 June 5; 510(7503): 92-101.
Xu, et al., Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions, NATURE MEDICINE, Volume 16, Number 5, May 2010, 592−598.
Morris, et al., Effects of Low−Dose Aspirin on Acute Inflammatory Responses in Humans, J Immunol 2009; 183:2089−2096; 13 July 2009.
Serhan, C., Novel N ω 3−derived local mediators in anti−inflammation and resolution, Pharmacology & Therapeutics 105 (2005) 7- 21.
Schwab, et al., Resolvin E1 and protectin D1 activate inflammation−resolution programmes, Nature, Vol 447, 14 June 2007, 869−875.
Ariota, et al., Stereochemical assignment, anti−inflammatory properties, and receptor for the omega−3 lipid mediator resolvin E1, J. Exp. Med., Vol. 201, No. 5, March 7, 2005 713-722.
Buckley, et al., Proresolving Lipid Mediators and Mechanisms in the Resolution of Acute Inflammation, Immunity 40, March 20, 2014, 315−327.
Ogata, et al., Effects of aspirin−triggered resolvin D1 on peripheral blood mononuclear cells from patients with Chagas’ heart disease, European Journal of Pharmacology 777 (2016) 26-32.
Lima−Garcia, et al., The precursor of resolvin D series and aspirin−triggered resolvin D1 display anti−hyperalgesic properties in adjuvant−induced arthritis in rats, British Journal of Pharmacology (2011) 164 278-293.
Kohli, Resolvins and protectins: mediating solutions to inflammation, British Journal of Pharmacology (2009), 158, 960-971.
Prescott and McKay, Aspirin−triggered lipoxin enhances macrophage phagocytosis of bacteria while inhibiting inflammatory cytokine production, Am J Physiol Gastrointest Liver Physiol 301: G487-G497, 2011.
Skarke, et al., Bioactive products formed in humans from fish oils, J. of Lipid Research, September 29, 2015, pages 1−42.
Sok, et al., Aspirin−triggered resolvin D1−modified materials promote the accumulation of pro−regenerative immune cell subsets and enhance vascular remodeling, Acta Biomaterialia (2017), 1−34.
Claims (32)
- アスピリン又はアスピリン様化合物を必要とする対象を特定することと、
サリチル酸メチルの供給源、アセチル供与体、及びL−アルギニンを含む組成物であって、前記胃で前記アスピリン又はアスピリン様化合物の悪影響を受けることなく、前記対象においてアスピリン誘発性レゾルビン類を作製するのに有効である組成物を、前記対象に提供することとを含む、
原位置でアスピリンを作製する方法。 - 前記サリチル酸メチルの供給源が冬緑油、つまりヒメコウジ油である、請求項1に記載の方法。
- 前記サリチル酸メチルの供給源がシラタマノキ属、カバノキ属、シモツケ属又はヒメハギ属である、請求項1に記載の方法。
- 前記サリチル酸メチルが10mgから60mgの量で与えられ、前記アセチル供与体が30mgから300mgの量で与えられ、又は前記L−アルギニンが3mgから40mgの量で与えられる、の少なくとも1つである、請求項1に記載の方法。
- 前記組成物をジェルキャップ、錠剤、散剤、クリーム剤、ローション剤、液剤、ソフトゲル剤、湿布、坐剤、又はセラム剤に充填することをさらに含む、請求項1に記載の方法。
- 前記組成物を経口、舌下、皮下、経皮、筋内、経鼻、皮内、経肺、肺胞内、膣内、直腸内、腹腔内又は静脈内投与用に調製することをさらに含む、請求項1に記載の方法。
- 前記組成物がアスピリン、アスピリン様生成物、又は別々に摂取するのと比較した場合、有効性の増加、及びオフターゲット効果の低下を示す、請求項1に記載の方法。
- 前記アセチル供与体が酢酸d,l−α−トコフェロール、ビタミンE、又はアセチル化ビタミンである、請求項1に記載の方法。
- オメガ3食物サプリメント、エイコサペンタエン酸(EPA)、ドコサヘキサエン酸(DHA)、あるいは1つ又は複数の緩衝剤の少なくとも1つを前記組成物に添加することをさらに含む、請求項1に記載の方法。
- 前記組成物が、蜜ろう、ラウリル硫酸アンモニウム、ラウレス硫酸ナトリウム、オレイルコハク酸ナトリウム、ラウリルスルホコハク酸アンモニウム、ドデシルベンゼンスルホン酸ナトリウム、ラウレス硫酸アンモニウム、N−ラウリルサルコシン酸ナトリウム、ラウリル硫酸ナトリウム、及びそれらの組み合わせから選択される乳化剤を含む、請求項1に記載の方法。
- サリチル酸メチルの供給源、アセチル供与体、及びL−アルギニンを含む組成物であって、前記胃で前記アスピリン又はアスピリン様化合物の悪影響を受けることなく、前記対象においてアスピリン誘発性レゾルビン類を作製するのに有効である組成物を含む、栄養サプリメント。
- 前記サリチル酸メチルの供給源が、冬緑油つまりヒメコウジ油である、請求項11に記載のサプリメント。
- 前記サリチル酸メチルの供給源が、シラタマノキ属、カバノキ属、シモツケ属、又はヒメハギ属である、請求項11に記載のサプリメント。
- 前記サリチル酸メチルが10mgから60mgの量で与えられ、前記アセチル供与体が30mgから300mgの量で与えられ、又は前記L−アルギニンが3mgから40mgの量で与えられる、の少なくとも1つである、請求項11に記載のサプリメント。
- 前記組成物が、ジェルキャップ、錠剤、散剤、クリーム剤、ローション剤、液剤、ソフトゲル剤、湿布、坐剤、又はセラム剤で与えられる、請求項11に記載のサプリメント。
- 組成物が経口、舌下、皮下、経皮、筋内、経鼻、皮内、経肺、肺胞内、膣内、直腸内、腹腔内又は静脈内投与用に調製される、請求項11に記載のサプリメント。
- 前記組成物が、アスピリン、アスピリン様生成物、又は別々に摂取するのと比較した場合、有効性の増加、及びオフターゲット効果の低下を示す、請求項11に記載のサプリメント。
- 前記アセチル供与体が、酢酸d,l−α−トコフェロール、ビタミンE、又はアセチル化ビタミンである、請求項11に記載のサプリメント。
- 組成物が、オメガ3食物サプリメント、エイコサペンタエン酸(EPA)、ドコサヘキサエン酸(DHA)、あるいは1つ又は複数の緩衝剤の少なくとも1つをさらに含む、請求項11に記載のサプリメント。
- 前記組成物が、蜜ろう、ラウリル硫酸アンモニウム、ラウレス硫酸ナトリウム、オレイルコハク酸ナトリウム、ラウリルスルホコハク酸アンモニウム、ドデシルベンゼンスルホン酸ナトリウム、ラウレス硫酸アンモニウム、N−ラウリルサルコシン酸ナトリウム、ラウリル硫酸ナトリウム、及びそれらの組み合わせから選択される乳化剤を含む、請求項11に記載のサプリメント。
- サリチル酸メチル、酢酸d,l−α−トコフェロール、ビタミンE、又はアセチル化ビタミン、L−アルギニン、エイコサペンタエン酸(EPA)及びドコサヘキサエン酸(DHA)を含む栄養サプリメントであって、対象においてアスピリン誘発性レゾルビン類を、前記対象の前記胃で前記アスピリン又はアスピリン様化合物の悪影響を受けることなく作製するのに有効である、サプリメント。
- 本質的にサリチル酸メチル、酢酸d,l−α−トコフェロール、ビタミンE、又はアセチル化ビタミン、L−アルギニン、エイコサペンタエン酸(EPA)及びドコサヘキサエン酸(DHA)からなる栄養サプリメントであって、対象においてアスピリン誘発性レゾルビン類を、前記対象の前記胃で前記アスピリン又はアスピリン様化合物の悪影響を受けることなく作製するのに有効である、サプリメント。
- 疼痛緩和又は心血管機能向上を必要とする対象を治療する方法であって、
アスピリン又はアスピリン様化合物を必要とする対象を特定することと;サリチル酸メチルの供給源、アセチル供与体、及びL−アルギニンを含む組成物であって、前記対象の前記胃で前記アスピリン又はアスピリン様化合物の悪影響を受けることなく、前記対象においてアスピリン誘発性レゾルビン類を作製するのに有効である組成物を前記対象に与えることと、を含む方法。 - 前記サリチル酸メチルの供給源が、冬緑油つまりヒメコウジ油である、請求項23に記載の方法。
- 前記サリチル酸メチルの供給源が、シラタマノキ属、カバノキ属、シモツケ属、又はヒメハギ属である、請求項23に記載の方法。
- 前記サリチル酸メチルが10mgから60mgの量で与えられ、前記アセチル供与体が30mgから300mgの量で与えられ、又は前記L−アルギニンが3mgから40mgの量で与えられる、の少なくとも1つである、請求項23に記載の方法。
- 前記組成物をジェルキャップ、錠剤、散剤、クリーム剤、ローション剤、液剤、ソフトゲル剤、湿布、坐剤、又はセラム剤に充填することをさらに含む、請求項23に記載の方法。
- 前記組成物を経口、舌下、皮下、経皮、筋内、経鼻、皮内、経肺、肺胞内、膣内、直腸内、腹腔内又は静脈内投与用に調製することをさらに含む、請求項23に記載の方法。
- 前記組成物が、アスピリン、アスピリン様生成物、又は別々に摂取するのと比較した場合、有効性の増加、及びオフターゲット効果の低下を示す、請求項23に記載の方法。
- 前記アセチル供与体が、酢酸d,l−α−トコフェロール、ビタミンE、又はアセチル化ビタミンである、請求項23に記載の方法。
- オメガ3食物サプリメント、エイコサペンタエン酸(EPA)、ドコサヘキサエン酸(DHA)、あるいは1つ又は複数の緩衝剤、オメガ3食物サプリメントの少なくとも1つを前記組成物に添加することをさらに含む、請求項23に記載の方法。
- 前記組成物が、蜜ろう、ラウリル硫酸アンモニウム、ラウレス硫酸ナトリウム、オレイルコハク酸ナトリウム、ラウリルスルホコハク酸アンモニウム、ドデシルベンゼンスルホン酸ナトリウム、ラウレス硫酸アンモニウム、N−ラウリルサルコシン酸ナトリウム、ラウリル硫酸ナトリウム、及びそれらの組み合わせから選択される乳化剤を含む、請求項23に記載の方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762484676P | 2017-04-12 | 2017-04-12 | |
US62/484,676 | 2017-04-12 | ||
US15/951,755 US10624907B2 (en) | 2017-04-12 | 2018-04-12 | Production of aspirin-triggered resolvins without the use of aspirin in a dietary omega-3 supplement |
US15/951,755 | 2018-04-12 | ||
PCT/US2018/027314 WO2018191505A1 (en) | 2017-04-12 | 2018-04-12 | Production of aspirin-triggered resolvins without the use of aspirin in a dietary omega-3 supplement |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2020516588A true JP2020516588A (ja) | 2020-06-11 |
Family
ID=63791346
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019552124A Pending JP2020516588A (ja) | 2017-04-12 | 2018-04-12 | オメガ3食物サプリメントにおけるアスピリン不使用のアスピリン誘発性レゾルビン類の作製 |
Country Status (6)
Country | Link |
---|---|
US (2) | US10624907B2 (ja) |
EP (1) | EP3609503A4 (ja) |
JP (1) | JP2020516588A (ja) |
KR (1) | KR102272558B1 (ja) |
SG (1) | SG11201909565WA (ja) |
WO (1) | WO2018191505A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020516588A (ja) | 2017-04-12 | 2020-06-11 | パフォーマンス ラブズ ピーティーイー,エルティーディー. | オメガ3食物サプリメントにおけるアスピリン不使用のアスピリン誘発性レゾルビン類の作製 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004071437A2 (en) * | 2003-02-07 | 2004-08-26 | Barmensen, Inc. | Compositions for enhancing sexual responsiveness |
US20060120975A1 (en) * | 2004-12-02 | 2006-06-08 | Colgate-Palmolive Company | Oral care composition comprising a phenolic compound and antioxidant vitamins and vitamin derivatives |
US20130195953A1 (en) * | 2012-01-27 | 2013-08-01 | Warsaw Orthopedic, Inc. | Methods and formulations for administration of anti-inflammatory compounds |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004078143A2 (en) | 2003-03-05 | 2004-09-16 | The Brigham And Women's Hospital Inc. | Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs |
JP2020516588A (ja) | 2017-04-12 | 2020-06-11 | パフォーマンス ラブズ ピーティーイー,エルティーディー. | オメガ3食物サプリメントにおけるアスピリン不使用のアスピリン誘発性レゾルビン類の作製 |
-
2018
- 2018-04-12 JP JP2019552124A patent/JP2020516588A/ja active Pending
- 2018-04-12 EP EP18783991.5A patent/EP3609503A4/en not_active Withdrawn
- 2018-04-12 SG SG11201909565W patent/SG11201909565WA/en unknown
- 2018-04-12 US US15/951,755 patent/US10624907B2/en active Active
- 2018-04-12 KR KR1020197029848A patent/KR102272558B1/ko active IP Right Grant
- 2018-04-12 WO PCT/US2018/027314 patent/WO2018191505A1/en unknown
-
2020
- 2020-03-19 US US16/823,739 patent/US11707469B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004071437A2 (en) * | 2003-02-07 | 2004-08-26 | Barmensen, Inc. | Compositions for enhancing sexual responsiveness |
US20060120975A1 (en) * | 2004-12-02 | 2006-06-08 | Colgate-Palmolive Company | Oral care composition comprising a phenolic compound and antioxidant vitamins and vitamin derivatives |
US20130195953A1 (en) * | 2012-01-27 | 2013-08-01 | Warsaw Orthopedic, Inc. | Methods and formulations for administration of anti-inflammatory compounds |
Non-Patent Citations (2)
Title |
---|
"Enhanced Virility Lotion", MINTEL GNPD ID970855, JPN6021021922, September 2008 (2008-09-01), ISSN: 0004689690 * |
健康食品による健康被害の未然防止と拡大防止に向けて, JPN6022002183, February 2016 (2016-02-01), ISSN: 0004689689 * |
Also Published As
Publication number | Publication date |
---|---|
EP3609503A1 (en) | 2020-02-19 |
SG11201909565WA (en) | 2019-11-28 |
KR102272558B1 (ko) | 2021-07-02 |
EP3609503A4 (en) | 2020-12-16 |
US20180296577A1 (en) | 2018-10-18 |
US20200215084A1 (en) | 2020-07-09 |
US10624907B2 (en) | 2020-04-21 |
WO2018191505A1 (en) | 2018-10-18 |
KR20190133696A (ko) | 2019-12-03 |
US11707469B2 (en) | 2023-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7442095B2 (ja) | ベータ-ヒドロキシブチレート及びブタンジオールのs-エナンチオマー並びにその使用方法 | |
RU2276975C2 (ru) | Терапевтические комбинации жирных кислот | |
AU2009309237B2 (en) | Fatty acids for use as a medicament | |
JP6092843B2 (ja) | 神経障害の治療用組成物 | |
JP2018203773A (ja) | アスタキサンチン抗炎症性相乗的組み合わせ | |
EP1754479A1 (en) | Capsule stable against mastication | |
WO2012002464A1 (ja) | ω3脂肪酸の配合製剤 | |
JP2004531568A (ja) | 補酵素qおよびエイコサペンタエン酸(epa) | |
AU762246B2 (en) | Method and composition for treatment of inflammatory conditions | |
JP2019052168A (ja) | オメガ−3脂肪酸およびトマトリコペンを含む抗炎症性相乗的組み合わせ | |
JP7206223B2 (ja) | パーキンソン病の予防および/または支持治療処置のための物質 | |
US11707469B2 (en) | Production of aspirin-triggered resolvins without the use of aspirin in a dietary omega-3 supplement | |
US20080160001A1 (en) | Antihypercholesterolemic Formulation with Less Side-Effects | |
KR20240036651A (ko) | 산화성 망막 질환의 진행을 억제하는 방법 | |
KR20230136627A (ko) | 포유 동물에서 체중 감소를 유도하기 위한 외인성 케톤 에스테르의 용도 | |
US9314435B2 (en) | Stable formulations of antiplatelet agents, omega-3 fatty acids and amylose in soft gelatin capsules | |
WO2020020317A1 (zh) | 二甲双胍复配组合物及其应用 | |
EP3801490A1 (en) | Compounds for use in cancer cachexia | |
BR112019012741A2 (pt) | composição, formulação, método para prevenir e/ou tratar caquexia em um indivíduo, uso da composição, e, produto de uso médico especial, produto de alimentos para uso específico de saúde, produto para alimentos para fins médicos especiais, produto de alimento para uso dietético especial, produto de nutrição médica e produto de alimento médico. | |
JP5759663B2 (ja) | 皮膚バリア機能改善剤等 | |
JP4473968B2 (ja) | 血球流動性改善剤 | |
JPWO2007049628A1 (ja) | 血液流動性改善剤 | |
WO2022130040A1 (en) | A pharmaceutical composition comprising fexofenadine, famotidine and melatonin | |
AU2021400074A1 (en) | A pharmaceutical composition comprising fexofenadine, famotidine and melatonin | |
CN105343072A (zh) | 一种用于减肥或治疗代谢综合征的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20210315 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210305 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210615 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210914 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20211115 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211203 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220125 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220418 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220621 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221019 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20221019 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20221019 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20221110 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20221115 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20221209 |
|
C211 | Notice of termination of reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C211 Effective date: 20221215 |